Morgan Stanley initiates ADARx Pharmaceuticals at Overweight with $32 target
Bullish analyst initiation with substantial implied upside, tempered by the absence of supporting detail.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst initiation with substantial implied upside, tempered by the absence of supporting detail.
What happened, with direct paths to the underlying reporting
Morgan Stanley initiated coverage of ADRX at Overweight with a $32 target versus the posted price of $17.63, implying roughly 81% upside. Analyst targets are opinions, and the record provides no supporting rationale.
Target: $32
Posted price: $17.63
Analyst firm: Morgan Stanley
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.